Gene test may predict who benefits from asthma drug
NCT ID NCT03694158
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at whether people aged 12 and older with a certain gene variant (IL-4RαR576) respond better to the asthma drug dupilumab. 150 participants will receive either dupilumab or a placebo for 48 weeks. The main goal is to see if the drug reduces asthma attacks more in those with the gene variant.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Dupilumab (Dupixent®)
What this could lead to
If successful, this could show that people with the IL-4RαR576 gene variant get better asthma control from dupilumab, leading to more personalized treatment.
What could go wrong
This is a Phase 4 trial, but results may not apply to everyone with asthma. The benefit may be small or not significant, and dupilumab can cause side effects like injection reactions or infections.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ASTHMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Boston Children's Hospital
Boston, Massachusetts, 02115, United States
-
Brigham and Women's Hospital
Boston, Massachusetts, 02115, United States
-
Henry Ford Health System
Detroit, Michigan, 48202, United States
-
MetroHealth System
Cleveland, Ohio, 44109, United States
-
Montefiore Einstein Clinical Research Center
The Bronx, New York, 10467, United States
-
University of Pennsylvania
Philadelphia, Pennsylvania, 19104, United States